These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24042480)

  • 1. Neuro-oncology: Glioblastoma prognosis linked to neuronal PD-L1 expression in tumour-adjacent tissue.
    Kingwell K
    Nat Rev Neurol; 2013 Nov; 9(11):602-3. PubMed ID: 24042480
    [No Abstract]   [Full Text] [Related]  

  • 2. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients.
    Liu Y; Carlsson R; Ambjørn M; Hasan M; Badn W; Darabi A; Siesjö P; Issazadeh-Navikas S
    J Neurosci; 2013 Aug; 33(35):14231-45. PubMed ID: 23986257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
    Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
    J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma.
    Vlahovic G; Fecci PE; Reardon D; Sampson JH
    Neuro Oncol; 2015 Aug; 17(8):1043-5. PubMed ID: 25964311
    [No Abstract]   [Full Text] [Related]  

  • 5. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.
    Heiland DH; Haaker G; Delev D; Mercas B; Masalha W; Heynckes S; Gäbelein A; Pfeifer D; Carro MS; Weyerbrock A; Prinz M; Schnell O
    Oncotarget; 2017 Jun; 8(26):42214-42225. PubMed ID: 28178682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
    Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
    Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
    Preusser M; Berghoff AS; Wick W; Weller M
    Clin Neuropathol; 2015; 34(6):313-21. PubMed ID: 26501438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
    Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
    Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis.
    Xue S; Song G; Yu J
    Sci Rep; 2017 Jun; 7(1):4231. PubMed ID: 28652622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
    Mansfield AS; Aubry MC; Moser JC; Harrington SM; Dronca RS; Park SS; Dong H
    Ann Oncol; 2016 Oct; 27(10):1953-8. PubMed ID: 27502709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
    Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
    Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 18. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages.
    Zhu Z; Zhang H; Chen B; Liu X; Zhang S; Zong Z; Gao M
    Front Immunol; 2020; 11():588552. PubMed ID: 33329573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of PD-L1 by Nitric Oxide via JNK Activation in A172 Glioblastoma Cells.
    Kiriyama Y; Tani A; Kadoya M; Okamoto R; Nochi H
    Biol Pharm Bull; 2020 Jun; 43(6):1020-1022. PubMed ID: 32201424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer.
    Mu L; Yu W; Su H; Lin Y; Sui W; Yu X; Qin C
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1036-1042. PubMed ID: 30983436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.